LUTATHERA

Project summary

LUTATHERA is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEPNETs) in adults. LUTHATHERA has first been used in the Erasmus MC and recently received FDA approval.